Lyell Immunopharma Inc Forecast, price target & analysts
Lyell Immunopharma Inc Target price 2025 - Analyst rating & recommendation
Lyell Immunopharma Inc Classifications & Recommendation:
Lyell Immunopharma Inc Price Target
| Target Price | $20.40 |
| Price | $28.36 |
| Deviation |
28.07%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Lyell Immunopharma Inc 2026 .
The average Lyell Immunopharma Inc target price is $20.40.
This is
28.07%
register free of charge
$26.25
7.44%
register free of charge
$12.12
57.26%
register free of charge
|
|
| A rating was issued by 8 analysts: 1 Analysts recommend Lyell Immunopharma Inc to buy, 3 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Lyell Immunopharma Inc stock has an average upside potential 2026 of
28.07%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.06 | 0.01 |
| 53.85% | 82.17% | |
| EBITDA Margin | -334,400.00% | -1,872,638.10% |
| 91.71% | 460.00% | |
| Net Margin | -571,650.00% | -2,031,880.00% |
| 216.73% | 255.44% |
6 Analysts have issued a sales forecast Lyell Immunopharma Inc 2025 . The average Lyell Immunopharma Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Lyell Immunopharma Inc EBITDA forecast 2025. The average Lyell Immunopharma Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
| 2024 | -334,400.00% | 91.71% |
|---|---|---|
| 2025 |
-1,872,638.10%
460.00%
Unlock
|
|
6 Lyell Immunopharma Inc Analysts have issued a net profit forecast 2025. The average Lyell Immunopharma Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2024 | -571,650.00% | 216.73% |
|---|---|---|
| 2025 |
-2,031,880.00%
255.44%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -26.23 | -11.28 |
| 40.27% | 57.00% | |
| P/E | negative | |
| EV/Sales | 26,342.67 |
6 Analysts have issued a Lyell Immunopharma Inc forecast for earnings per share. The average Lyell Immunopharma Inc EPS is
This results in the following potential growth metrics and future valuations:
Lyell Immunopharma Inc...
Current Lyell Immunopharma Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| LUCID CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 24 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 16 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Oct 30 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 24 2025 |
|
Locked
LUCID CAPITAL MARKETS:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 24 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 16 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 12 2024 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Oct 30 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
